Pancreatic Cancer Research: New Preclinical Studies Explore Combination Therapies and Early Intervention
New preclinical research has explored several therapeutic approaches for pancreatic cancer, focusing on combination drug regimens and early intervention strategies in mouse models. These studies, published in PNAS, Science, and other journals, aim to address the disease's high mortality rate, treatment resistance, and often late diagnosis by targeting key molecular pathways, including the KRAS gene and associated signaling nodes.
Addressing the disease's high mortality rate, treatment resistance, and often late diagnosis, researchers are targeting key molecular pathways, including the KRAS gene.
Triple-Drug Therapies Target Established Tumors
Researchers at the Spanish National Cancer Research Centre (CNIO) have identified a triple-drug therapy that demonstrated complete and lasting regression of pancreatic ductal adenocarcinoma (PDAC) in various preclinical models. PDAC is the most common and lethal form of pancreatic cancer, characterized by a five-year survival rate of approximately 13% and frequent resistance to standard treatments.
The therapy simultaneously targets three signaling pathways crucial for tumor growth and survival: RAF1, EGFR family receptors, and STAT3. This strategy was developed after earlier research by senior study author Carmen Guerra indicated that blocking single KRAS-related pathways led to tumors activating alternative survival mechanisms, such as STAT3.
The combination therapy consists of:
- Daraxonrasib (RMC-6236): An investigational drug designed to target KRAS.
- Afatinib: An FDA-approved drug for certain lung cancers, which inhibits the EGFR family of receptors.
- SD36: A novel compound engineered to disable STAT3.
This regimen was tested across three distinct mouse models: mice with implanted mouse tumor cells in the pancreas, genetically engineered mice designed to develop pancreatic cancer, and immune-deficient mice carrying human tumor samples (patient-derived xenografts). In all models, the treatment resulted in the complete elimination of tumors and restoration of the pancreas to a healthy state.
Tumors did not return for at least 200 days (approximately seven months) post-treatment, indicating prevention of resistance. The therapy was observed to be well-tolerated in mice, reportedly showing no debilitating side effects and maintaining similar body weight, blood counts, metabolic markers, and organ health compared to placebo groups. Researchers noted that while the therapy showed no side effects in mice, some components like afatinib are known to cause side effects in humans, suggesting the need for further investigation into alternative drugs or modifications for human application.
Cancer Interception Strategy Targets Precancerous Lesions
A separate preclinical study conducted by physician-scientists at the Perelman School of Medicine at the University of Pennsylvania and Penn Medicine's Abramson Cancer Center explored the concept of "cancer interception" for pancreatic cancer. Published in Science, this research focused on eliminating precancerous cells before they develop into full-fledged tumors, a strategy distinct from cancer prevention.
The study utilized two experimental inhibitors targeting the KRAS gene—RMC-9945 and RMC-7977 (a tool compound representing daraxonrasib)—which is mutated in over 90% of pancreatic cancers. These compounds were designed to inhibit active RAS, a driver of cancer growth. Most PDAC tumors originate from microscopic lesions called PanINs (pancreatic intraepithelial neoplasias), which are typically too small for detection by scans and consistently carry KRAS mutations.
In an immunocompetent mouse model, an intervention group received either RMC-9945 or RMC-7977 after PanIN development but before tumor formation. Researchers observed a reduction in precancerous lesions within 10 days, with a more significant reduction after 28 days of treatment. This early intervention led to slower tumor development and increased survival in mice.
Long-term treatment with RMC-7977 in PanIN-bearing mice tripled the median overall survival time compared to untreated controls. Furthermore, the intervention group treated before tumor development survived nearly twice as long as the group treated only after cancer development.
The research team plans to translate these findings into clinical trials for high-risk patients, such as individuals monitored for pancreatic cysts or those with a genetic predisposition to pancreatic cancer (e.g., those with BRCA1, BRCA2, or PALB2 gene mutations, or hereditary pancreatitis).
Overcoming CDK4/6 Inhibitor Resistance with EGFR Combination
Another line of research investigated strategies to enhance the effectiveness of CDK4/6 inhibitors, which indirectly suppress oncogenic KRAS signaling. While CDK4/6 inhibitors initially induced cellular senescence in pancreatic cancer cells, they did not cause sufficient cell death as a monotherapy. This limitation was linked to a paradoxical increase in ERK activity following CDK4/6 inhibition, which attenuated antitumor effects.
This ERK reactivation was traced to the activation of the epidermal growth factor receptor (EGFR), occurring due to the senescence-associated secretory phenotype (SASP) where senescent cells secrete EGFR-stimulating ligands.
This cascade enhanced pro-survival pathways, contributing to resistance to CDK4/6 inhibitor-induced cell death.
Based on these insights, researchers investigated combination therapies involving CDK4/6 inhibitors and EGFR-targeting agents, such as the EGFR tyrosine kinase inhibitor gefitinib or the anti-EGFR monoclonal antibody cetuximab. These combinations demonstrated strong therapeutic efficacy in both in vitro and in vivo models of pancreatic cancer. The mechanism involves CDK4/6 inhibition initially inducing cellular senescence, followed by EGFR inhibition selectively triggering cell death in these senescent cells, a process termed senolysis.
Studies in mouse models indicated that CDK4/6 inhibition did not induce detectable senescence in normal tissues, suggesting a potential therapeutic window. Given that this strategy utilizes existing, clinically approved agents, it is anticipated to facilitate translation into clinical trials.
Future Outlook
These preclinical studies represent diverse approaches to addressing pancreatic cancer, ranging from multi-targeted therapies for established tumors to early interception of precancerous lesions and strategies to overcome treatment resistance. A common element across much of this research is the critical role of KRAS mutations and associated pathways in driving the disease.
While these findings in mouse models and cell lines offer insights into potential new treatments, further research and human clinical trials are necessary to determine their safety and efficacy in patients. Researchers continue to emphasize the genetic diversity of pancreatic tumors, indicating the need for varied and personalized therapeutic strategies.